To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study
(NCT00604383), and who are felt by the investigator to have the potential to benefit from the
ruboxistaurin treatment. Patients must be off study drug for 6 to 18 months from completion
of B7A-MC-MBCM before beginning B7A-MC-MBDV. Additional data will be gathered to determine
the long-term safety and effect of ruboxistaurin on vision.